Please login to the form below

Not currently logged in
Email:
Password:

respiratory syncytial virus

This page shows the latest respiratory syncytial virus news and features for those working in and with pharma, biotech and healthcare.

Synairgen’s SNG001 advances into phase 3 COVID-19 trial

Synairgen’s SNG001 advances into phase 3 COVID-19 trial

restore the lung’s immune response and accelerate recovery from COVID-19,” said Tom Wilkinson, professor of respiratory medicine at the University of Southampton and lead author of the study. ... This might carry additional advantages of treating

Latest news

More from news
Approximately 2 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • COVID-19: the race to find a vaccine COVID-19: the race to find a vaccine

    In the absence of a knockout antiviral, researchers are trying to mitigate harmful effects of the virus. ... Scientists have since industrialised the concept, leading to the development of antibodies against Ebola and respiratory syncytial virus.

  • Getting multichannel marketing right Getting multichannel marketing right

    has encouraged people to knit hats and blankets for babies to alert people to respiratory syncytial virus.

  • Deal Watch March 2017 Deal Watch March 2017

    In order to focus its respiratory resources on products such as Symbicort and benralizumab, AstraZeneca has agreed that its product Tudorza (marketed for COPD) and Duaklir (in phase III for COPD) ... Headline. $m. AstraZeneca/ MedImmune. Sanofi Pasteur.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Alios has an oral anti-viral in phase 2 for treatment of infant respiratory syncytial virus (RSV) which complements J&J's early stage programmes in RSV.

  • Pharma deals during June 2013 Pharma deals during June 2013

    Still in the respiratory space, Teva acquired the privately owned drug delivery company MicroDose Therapeutx for an initial $40m with further payments of up to $125m. ... The deal brings to Teva a multi dose dry powder nebuliser technology and MDT-637, a

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics